The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Regulatory News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.125
Bid: 17.75
Ask: 18.50
Change: 0.00 (0.00%)
Spread: 0.75 (4.225%)
Open: 18.125
High: 18.125
Low: 18.125
Prev. Close: 18.125
OPTI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Joint venture with Nizo Food Research

21 Jan 2015 07:00

RNS Number : 6843C
OptiBiotix Health PLC
21 January 2015
 



OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Joint venture agreement with NIP B.V., a wholly owned undertaking of NIZO Food Research

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces that it has entered into a 50/50 joint venture ('JV') agreement with NIP B.V., a wholly owned undertaking of NIZO Food Research BV ('NIZO').

 

As announced 28 October 2014, OptiBiotix incorporated its weight management formulation into fruit yoghurts which were manufactured by NIZO. An organoleptic (tasting) panel reported the yoghurt products had a smooth feel and taste and had the appearance of conventional yoghurts. These results have led to this JV agreement which has been established to develop, manufacture and distribute (both directly and indirectly) the weight management yoghurt and other dairy products to global markets. NIZO provides manufacturing expertise, industry credibility and a global network of contacts in the dairy industry. This agreement will allow OptiBiotix to fast-track entry into global markets. Both companies are contributing background intellectual property (IP), with any new IP jointly owned.

 

OptiBiotix has a strategy to partner with multiple organisations and this JV agreement creates an opportunity to access global markets to commercialise the weight management formulation in yoghurt and other dairy products. This JV agreement comes about following the Company's attendance at the Health Ingredients Europe conference in December 2014, where OptiBiotix attracted interest in the product from Europe, the USA, South Korea, and Japan.

Stephen O'Hara, CEO of OptiBiotix, commented: "Our weight management formulation has been especially created by industry experts to enhance satiation (feeling of fullness), increase metabolism and reduce energy harvest (calorie intake). Successful manufacturing and tasting studies of our weight management formulation in yoghurts, coupled with early commercial interest and NIZO's industry credibility, has allowed us to advance this opportunity earlier than expected. This announcement is consistent with OptiBiotix's strategy of creating technology platforms which create multiple product and partnering opportunities and is the start of a process to build a strong and sustainable business."

 

 

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below

Cairn Financial Advisers LLP

Tel: 020 7148 7900

Liam Murray / Avi Robinson

 

Hybridan LLP (Joint Broker)

Claire Louise Noyce

 

 

Tel: 020 3713 4581

Peterhouse Corporate Finance Ltd (Joint Broker)

Tel: 020 7469 0936

Lucy Williams / Duncan Vasey

Walbrook PR Ltd

Tel: 020 7933 8780 or optibiotix@walbrookpr.com

Anna Dunphy

Mob: 07876 741 001

Mike Wort

Mob: 07900 608 002

 

About OptiBiotix- www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

About NIZO - www.nizo.com

 

NIZO is one of the most advanced, independent contract research companies in the world and works with both small and multinational food and ingredient companies to develop and produce innovative products for the food and drink industry. NIZO has one of the largest food-grade pilot plants in Europe, and more than 65 years' experience and expertise in product manufacture.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
JVELLFVDLFIIFIE
Date   Source Headline
2nd Aug 20167:00 amRNSAppointment of Director of Business Development
28th Jul 20162:30 pmRNSHolding(s) in Company
26th Jul 20167:00 amRNSCompletion of pilot launch and creation of JV
14th Jul 20167:00 amRNSNew patent filing
5th Jul 20167:00 amRNSStrategy update
4th Jul 20163:36 pmRNSHolding(s) in Company
30th Jun 20163:06 pmRNSExercise of Warrants and Issue of Equity
17th Jun 20164:40 pmRNSSecond Price Monitoring Extn
17th Jun 20164:35 pmRNSPrice Monitoring Extension
2nd Jun 201612:18 pmRNSExercise of Warrants and Issue of Equity
19th May 20167:00 amRNSNew patent filing
10th May 201612:39 pmRNSResult of AGM
20th Apr 201612:18 pmRNSExercise of Warrants and Issue of Equity
14th Apr 20167:00 amRNSFinal Results
7th Apr 20167:00 amRNSResults of cholesterol human volunteer study
5th Apr 20167:00 amRNSJoint development agreement signed with Royal DSM
24th Mar 20167:00 amRNSExercise of Warrants and Issue of Equity
23rd Mar 20167:00 amRNSNotice of Results
22nd Mar 20167:00 amRNSSecond contract signed for Sweetbiotix
17th Mar 20167:00 amRNSJV agreement with the University of Manchester
26th Feb 201610:57 amRNSExercise of Warrants and Issue of Equity
19th Feb 201610:12 amRNSExercise of Warrants and Issue of Equity
12th Feb 20169:49 amRNSExercise of Warrants and Issue of Equity
5th Feb 20167:00 amRNSPlacing
28th Jan 201612:51 pmRNSInvestor presentation - change of venue
26th Jan 20167:00 amRNSExercise of Warrants and Issue of Equity
20th Jan 20167:00 amRNSInvestor presentation
19th Jan 20167:00 amRNSScientific Advisory Group appointment
13th Jan 20167:00 amRNSCommercial agreement signed with KSF Acquisition
21st Dec 20157:00 amRNSCompletion of Placing, Total Voting Rights
11th Dec 20151:30 pmRNSCorrection: Exercise of Warrants & Issue of Equity
11th Dec 201511:30 amRNSExercise of Warrants and Issue of Equity
7th Dec 20157:00 amRNSPlacing and Directors' Dealings
24th Nov 20157:00 amRNSDirectorate Change
20th Nov 20157:00 amRNSDevelopment agreement signed with CSL
16th Nov 201510:49 amRNSExercise of Warrants and Issue of Equity
5th Nov 20154:40 pmRNSSecond Price Monitoring Extn
5th Nov 20154:35 pmRNSPrice Monitoring Extension
3rd Nov 20157:00 amRNSNew patent filings
7th Oct 201512:30 pmRNSHolding(s) in Company
7th Oct 20157:00 amRNSNew microbial strain registrations
29th Sep 20157:00 amRNSCompletion of human studies
18th Sep 20154:18 pmRNSExercise of Warrants and Issue of Equity
27th Aug 20157:00 amRNSHalf Yearly Report
11th Aug 201512:08 pmRNSResult of AGM
28th Jul 20157:00 amRNSCompletion of human studies
9th Jul 20157:00 amRNSContract signed with Instituto de Química Orgánica
23rd Jun 20155:00 pmRNSHolding(s) in Company
17th Jun 20154:59 pmRNSExercise of Warrants and Issue of Equity
12th Jun 20152:05 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.